Genome-wide DNA methylation landscape defines specialization of regulatory T cells in tissues

Michael Delacher[#1], **Charles D. Imbusch**[#2], **Dieter Weichenhan**[3], **Achim Breiling**[4], **Agnes Hotz-Wagenblatt**[5], **Ulrike Träger**[1], **Ann-Cathrin Hofer**[1], **Danny Kägebein**[1], **Qi Wang**[2], **Felix Frauhammer**[2], **Jan-Philipp Mallm**[6,7], **Katharina Bauer**[6,7], **Carl Herrmann**[8], **Philipp Lang**[9], **Benedikt Brors**[2,10,11], **Christoph Plass**[3], and **Markus Feuerer**[1,12]

[1]Immune Tolerance Research Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany

[2]Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany

[3]Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany

[4]Division of Epigenetics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany

[5]Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany

[6]Research Group Genome Organization & Function, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany

[7]Heidelberg Center for Personalized Oncology (DKFZ-HIPO), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany

[8]Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany

[9]Department of Molecular Medicine II, Heinrich-Heine University Düsseldorf, Universitätsstrasse 1, 40225 Düsseldorf, Germany

[10]National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany

[11]German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany

Correspondence should be addressed to M.F. (m.feuerer@dkfz-heidelberg.de).

¹²Institute of Immunology, Regensburg Center for Interventional Immunology (RCI), University Regensburg and University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany

[#] These authors contributed equally to this work.

Abstract

Regulatory T cells (T_{reg}) perform two distinct functions: they maintain self-tolerance and support organ homeostasis by differentiation into specialized tissue T_{reg} cells. We now report that epigenetic modifications define molecular characteristics of tissue T_{reg} cells. Tagmentation-based whole-genome bisulfite sequencing of tissue and lymphoid T cells revealed more than 11,000 differentially methylated regions. Similarities of the epigenetic landscape led to the identification of a common tissue T_{reg} population, present in many organs and characterized by gain and loss of DNA methylation, including many T_H2-associated sites such as the IL-33 receptor ST2, and the production of tissue-regenerative factors. Furthermore, this ST2-expressing population (which we term here tisT_{reg}ST2) was dependent on the transcriptional regulator BATF and could be expanded by IL-33. Thus, tissue T_{reg} cells integrate different waves of epigenetic reprogramming which define their tissue-restricted specializations.

Regulatory T cells (T_{reg}) are critical to maintain self-tolerance. They modulate the functions of different immune cells, thereby affecting a variety of conditions, including autoimmunity, cancer, allergy and inflammation[1, 2]. In addition, it is becoming increasingly clear that specialized T_{reg} cells in tissues are important to promote organ homeostasis, a function that was initially only attributed to tissue-resident macrophages[3]. In fat (visceral adipose tissue), T_{reg} cells support metabolic functions and express PPAR-γ, a master-regulator of adipocyte differentiation[3, 4, 5], and the IL-33R alpha chain (ST2)[6]. Other examples of tissue homeostasis promoted by specialized T_{reg} cells include injured skeletal muscles and lungs after influenza A infection[7, 8]. In both cases, T_{reg} cells present in damaged tissues produce amphiregulin (AREG), an epidermal growth factor receptor ligand important for tissue repair[7, 8].

The molecular mechanisms by which tissue-resident T_{reg} cells acquire and stabilize their 'tissular' program are poorly understood. Epigenetic modifications have been linked to establishing tissue-resident characteristics in macrophages[9, 10]. Similar mechanisms could be important to shape the tissue identity of T_{reg} cells.

Our methylome analysis revealed 11,000 differential methylated regions (DMRs) associated with about 4,000 genes. Shared epigenetic profiles led to the identification of a common tissue T_{reg} population, characterized by the epigenetic reprogramming of parts of the T-helper 2 (T_H2) pattern and production of the tissue regenerative factor AREG. Our data suggest that epigenetic events shape the characteristics and function of tissue T_{reg} cells.

Results

Identification of differentially methylated regions

To investigate the tissue-specific program of T_{reg} cells, we performed low-input tagmentation-based whole-genome bisulfite sequencing (TWGBS) to decipher the DNA methylome of T_{reg} cells isolated from different tissues. Utilizing *Foxp3*-reporter mice, we isolated T_{reg} cells from abdominal fat depots, skin, liver and inguinal lymph nodes (LN), and included conventional CD4$^+$ T cells (T_{conv}) from LN as a control population (Fig. 1a and Supplementary Fig. 1). Three independent replicates per sample were performed and robust data were obtained for all samples with reproducible replicates, with about $7x10^8$ total reads per group and an average 20-fold coverage for each CpG per population (Supplementary Fig. 2a). In pairwise comparisons, a strict definition of at least 30% difference in DNA methylation was chosen and revealed about 11,000 unique differentially methylated regions (DMRs) (Fig. 1b, c and Supplementary Fig. 2b). The average length of a DMR was about 1 kilo base pairs (kb), and annotation with genomic features derived from Refseq illustrated that the majority of DMRs were located in intragenic regions (63%), whereas promoter and intergenic regions comprised only 9% and 28%, respectively (Fig. 1c and Supplementary Fig. 2c,d). We observed a peak of DMRs located immediately downstream of transcription start sites (TSS) (Fig. 1d). Principal component analysis (PCA) showed that the methylation patterns of fat and skin T_{reg} were more similar to each other and rather distinct from LN T_{reg} and T_{conv} (Fig. 1b, e). These results indicate that T_{reg} cells in tissues have a distinguishable methylation pattern.

RNA transcriptome analysis supports DNA methylation pattern

We performed RNA sequencing (RNAseq) of T_{reg} cells and T_{conv} cells from tissues. The RNA transcriptome analysis revealed substantial gene expression differences between T_{reg} cells from tissues and LN. 3,072 and 4,698 genes were differentially expressed between fat or skin and LN T_{reg} cells, respectively. The comparison between fat and skin-resident T_{reg} cells showed 552 genes to be differentially expressed (Fig. 2a). Unsupervised hierarchical clustering of the RNAseq data confirmed this notion and grouped fat and skin T_{reg} cells close together, whereas liver T_{reg} located closer to LN T_{reg} cells (Fig. 2b). Hierarchical clustering of DMR methylation data resulted in a very similar grouping, suggesting that gene expression and DNA methylation patterns are interconnected (Fig. 2c). Indeed, integrated analysis of both datasets showed a negative correlation of gene expression and DMR methylation (median -0.303) (Fig. 2d), indicating that, in many cases, hypomethylation of a DMR correlated with the expression of the corresponding gene and vice versa. Such a correlation has been observed in similar studies[11].

T_{reg} cell-specific epigenetic signature

Methylation-based analyses of candidate regions have previously helped distinguish T_{reg} from T_{conv} cells. The most prominent example is a T_{reg}-specific demethylated region in the *Foxp3* gene, located in the first intron and termed conserved non-coding sequence 2 (CNS2)[1, 12]. This analysis has been extended by using methylated DNA immunoprecipitation (MeDIP) to analyze differences between T_{reg} and T_{conv} cells from lymphatic organs[13]. That study identified a T_{reg} cell-specific CpG hypomethylation pattern

that was established in the thymus and included, in addition to *Foxp3,* other T_{reg} signature genes13. Since our data set included T_{reg} and T_{conv} cells from LN, we first focused our analysis on this signature established in the thymus. Pairwise comparison between LN T_{reg} and T_{conv} cells revealed 339 DMRs (Fig. 1c). When plotting the mean methylation difference (LN T_{reg} – LN T_{conv}) of promoter and intragenically located DMRs against RNA expression data of the corresponding genes, we identified a clear anti-correlation of demethylation being associated with increased gene expression, and gain of methylation with gene repression (Fig. 3a). Our data confirmed T_{reg}-specific hypomethylation at sites described in the earlier study13, e.g. at *Ctla4, Ikzf2, Ikzf4,* and *Il2ra* (Fig. 3b), while we also identified several novel hypomethylated sites linked to genes such as *Ccr6, Cish* and *Ift80.* Furthermore, we identified previously unappreciated hypermethylated regions in genes that were underrepresented in T_{reg} cells, such as *Itk, Satb1, Cox10, Fam78a* and *Tgfbr2* (Supplementary Fig. 3).

Since TWGBS allows resolution at a single CpG level, we used this to study the *Foxp3* gene. The T_{reg}-specific demethylation of *Foxp3* went far beyond the CNS2 region initially described12, and spanned the entire first intron. Starting from exon 2, the remaining gene was methylated in T_{reg} cells (Fig. 3c and Supplementary Fig. 4). To verify our whole-genome sequencing data with a complementary method, we selected several regions in the *Foxp3* gene and performed PCR-based amplification of bisulfite converted DNA, followed by sequencing of these amplicons (Fig. 3d-f and Supplementary Table 1). The amplicon sequencing data confirmed and validated the whole-genome methylation data and, additionally, established that demethylation of the entire intron 1, as well as an upstream region 1, could occur during differentiation of T_{reg} cells in the thymus (Fig. 3d and Supplementary Fig. 5). Furthermore, this *Foxp3* pattern was shown to be present in naive T_{reg} cells, but not in *in vitro* transforming growth factor-β (TGF-β)-induced (iT_{reg}) cells (Fig. 3e and Supplementary Fig. 6). In addition, methylation at the *Foxp3* gene was not responsible for differences in *Foxp3* expression levels (Supplementary Fig. 7).

To further investigate the universality of this T_{reg}-specific methylation signature, we isolated peripherally-induced (pT_{reg}) and thymus-derived T_{reg} cells (tT_{reg}). pT_{reg} cells are characterized by the expression of the transcription factor RORγt and do not express the transcription factor HELIOS (*Ikzf2*), whereas tT_{reg} cells do not express RORγt, but express HELIOS14. We sorted both populations from the spleen and performed PCR-based amplification of bisulfite converted DNA for regions in *Ctla4, Ikzf2, Il2ra* and *Foxp3.* Although *Ctla4, Il2ra* and *Foxp3* were uniformly hypomethylated in both T_{reg} populations, *Ikzf2* was completely methylated in pT_{reg} cells, identifying differences in methylation of *Ikzf2* as an epigenetic mark to differentiate between pT_{reg} and tT_{reg} cells (Fig. 3g and Supplementary Fig. 8).

In summary, TWGBS is a powerful method to study T_{reg} cell-specific methylation differences at a single CpG level.

Epigenetic landscape of tissue T_{reg} cells

While pairwise comparison between LN T_{reg} and T_{conv} cells identified 339 DMRs, the number of DMRs between fat or skin T_{reg} versus LN T_{reg} was about 5-fold larger (1,593 and

1,645 DMRs, respectively) (Fig. 1c). Many of the DMRs were shared between fat versus LN and skin versus LN T_{reg} cells, indicating either common effector/memory or specific tissue T_{reg} programs (Fig. 4a). We extracted 106 genes that showed differential methylation and corresponding gene expression changes in both comparisons (Fig. 4b). To differentiate between common effector/memory and tissue T_{reg} programs, we compared this signature with RNAseq data from T_{conv} cells isolated from the same peripheral tissue (Fig. 4b and Supplementary Fig. 9). Although individual genes of this list could be identified as common effector/memory related, e.g. *Foxp1* or *Lef1*, the majority of the 106 genes were part of tissue T_{reg} programs and not just common effector/memory related. Pairwise comparisons of T_{reg} and CD4 non-T_{reg} cells from the same tissue revealed that the signature of 106 genes was highly significantly biased towards tissue T_{reg} cells (Supplementary Fig. 9b).

In many cases, methylation at the promoter sites was similar between the groups, but started to be differential just after the TSS in the first intron, as observed in the *Foxp3* gene (Fig. 4c and Supplementary Fig. 10). For selected genes, we confirmed differential expression at the protein level via flow cytometry (Fig. 5a). For example, *Klrg1* displayed hypomethylation in tissue T_{reg} cells, and was expressed by more than 80% of T_{reg} cells in the skin and fat, but only by about 10% of T_{reg} cells from LN. Hypomethylation and expression of TIGIT and ST2 behaved similarly. The strong changes in protein expression observed for TIGIT, KLRG1 and ST2, were not found in T_{conv} cells isolated from skin and fat (Fig. 5a).

In addition to shared characteristics, we were also interested in differences between tissue T_{reg} cells (Fig. 5b). The comparison between fat and skin T_{reg} cells revealed that the key transcription factor of visceral adipose tissue T_{reg} differentiation, *Pparg,* was hypomethylated in fat T_{reg} cells and, concomitantly, the gene was also highly expressed (Fig. 5c). On the other hand, skin T_{reg} cells had several specifically hypomethylated gene loci, including *Ahr, Icos, Itgae* (CD103) and *Gpr55*, and all corresponding genes were overexpressed in skin T_{reg} cells (Fig. 5b, d, e and Supplementary Fig. 11).

Overall, these results showed that the epigenetic landscape of fat and skin T_{reg} cells shared many characteristics.

Epigenetic reprogramming of T_H2-associated loci

To further delineate common principles of tissue T_{reg} cells, a gene ontology (GO) analysis of the 106 genes with differential methylation and expression patterns (Fig. 4b) was performed. At the top of the list were GO terms describing T cell differentiation (Fig. 6a). Four transcription factors were particularly enriched in these lists, namely *Gata3, Irf4, Rora,* and *Batf,* all of which were hypomethylated and overexpressed in fat and skin T_{reg} cells (Fig. 6b and Supplementary Fig. 12). GATA-3 and IRF4 are key transcription factors determining the T_H2 fate decision of CD4[+] T cells[15]. To probe whether fat and skin T_{reg} cells show a generalized type-2 profile, a selected list of diagnostic T_H2 probes[16] was used to plot skin T_{reg} versus LN T_{reg} and fat T_{reg} versus LN T_{reg} cells. In both cases, T_H2 overexpressed as well as T_H2 underrepresented genes were significantly biased towards the respective tissue T_{reg} site, indicating a type-2 polarization (Fig. 6c). For example, *Il1rl1* (encoding for ST2) and *Il10,* both associated with type-2 conditions[15, 17], were hypomethylated in tissue T_{reg} cells. *Il10* displayed two hypomethylation regions, one about 9 kb upstream of the promoter

and a second intragenic region. The upstream region falls into a previously described DNaseI hypersensitive site of the *Il10 locus* in T_H2 cells[18]. The *Il1rl1* (ST2) gene was hypomethylated in the first intron, and about 90% of the fat T_{reg} and 60% of skin T_{reg} cells expressed ST2, as compared to less than 10% in the spleen counterpart (Fig. 6d and Supplementary Fig. 13). If tissue T_{reg} cells from fat and skin were type-2 biased, it should be possible to recapitulate parts of their phenotype by treating lymphoid T_{reg} cells with IL-4. Indeed, IL-4 treatment of lymphoid T_{reg} cells strongly induced the expression of *Gata3, Irf4, Il1rl1* and *Il10,* but repressed *Ms4a4b*, a T_H1-associated gene, underrepresented in tissue T_{reg} cells, in a dose-dependent manner (Fig. 6e and Supplementary Fig. 14).

Demethylation at CG sites can allow transcription factors (TF) to modulate gene transcription[19]. We studied the TF binding motifs that were enriched in hypomethylated DMRs found in fat and skin T_{reg} cells, and represented in cluster 2 (Fig. 6f; upper panel). Among the twelve TF with an enrichment of their binding motif in cluster 2, eleven were also overexpressed in fat and skin T_{reg} cells, including *Rora, Batf,* and different members of the *Jun* and *Fos* family (Fig. 6f; lower panel). The BATF-JUN complex promotes DNA binding of the transcription factor IRF4 and the IRF4–JUN–BATF heterotrimeric complex was shown to be critical for IRF4-mediated transcription in T cells[20], thereby, the complex may reinforce type-2 polarization.

Characterization of tissue ST2⁺ T_{reg} cells

We called the here identified T_H2-biased subset of T_{reg} cells, expressing ST2 and dominating the T_{reg} population in fat and skin tissue, 'tissue T_{reg} ST2 cells' (tisT_{reg}ST2). They are characterized by epigenetic and gene expression differences of 106 genes (Fig. 4b), such as *Gata3, Irf4, Batf, Rora, Maf, Il1rl1, Il10, CD200r1, Tigit,* and *Klrg1.* Fat and skin T_{reg} cells showed demethylation and overexpression of *Maf* (*c-maf*), an originally described T_H2 cell-associated TF able to bind to the *Il10* promoter and induce *Il10* transcription[18]. In addition, one of the fundamental characteristics of tisT_{reg}ST2 cells is the expression of AREG, a T_H2-associated epidermal growth factor receptor ligand[21]. The *Areg* gene locus harbored two hypomethylated regions upstream of the promoter in fat and skin T_{reg} cells (Supplementary Fig. 15).

Since expression of ST2, KLRG1, TIGIT and GATA-3 characterized tisT_{reg}ST2 cells in fat and skin, we used these markers to screen a number of organs for the presence of this cell type. While fat and skin had the highest fraction of tisT_{reg}ST2 within the Foxp3-positive T_{reg} compartment (about 80-90% and 50-60%, respectively), other peripheral organs such as lung, bone marrow and liver contained 10-20% of them, and lymphoid organs had the lowest fraction with less than 5%, (Fig. 7a, b). We could not detect a ST2⁺KLRG1⁺ population in the T_{conv} compartment in skin, liver, blood, BM, lung, and only a minor (< 5%) population in fat tissue (Supplementary Fig. 16a). While tisT_{reg}ST2 cells from the different organs similarly expressed, for example, high levels of GATA-3, the corresponding T_{conv} population did not resemble tisT_{reg}ST2 characteristics (Fig. 7a and Supplementary Fig. 9b, 16b, c).

To further study the influence of T cell receptor (TCR) signaling and activation on the tisT_{reg}ST2 population within the T_{reg} compartment in tissues, we separated T_{reg} cells based on different expression levels of CD44, an effector/memory marker. The tisT_{reg}ST2

population was almost exclusively located in the CD44-high effector/memory compartment (Supplementary Fig. 17a), which is in accordance with previous literature of tissue-resident T_{reg} cells being of effector/memory phenotype22. Since high expression of CD44 in tisT$_{reg}$ST2 suggested a previous activation event via TCR-signaling, we analyzed this population in *Nr4a1* (which encodes Nur77)-GFP reporter mice, where TCR signal strength is measured by reporter activity23. Therefore, we subdivided the T_{reg} pool in GFP-high, GFP-intermediate and GFP-negative fractions to study whether the presence of tisT$_{reg}$ST2 cells depends on ongoing TCR signaling. Although the frequency of tisT$_{reg}$ST2 was much lower in the lymphatic organs as compared to the fat tissue (1-2% vs. 90%, respectively), the per-organ fraction of tisT$_{reg}$ST2 was not influenced whether current TCR-signaling was on or off (Supplementary Fig. 17b).

Next, we wanted to elaborate whether tisT$_{reg}$ST2 cells could be part of the induced T_{reg} population in tissues. Previous publications have described that the colon harbors two distinct T_{reg} populations, pT$_{reg}$ and tT$_{reg}$ cells14. Unlike HELIOS$^+$RORγt$^-$ tT$_{reg}$ cells, pT$_{reg}$ cells are induced by commensal bacteria in the colon. TisT$_{reg}$ST2 cells were only present in the tT$_{reg}$ population of the colon, where they represented about 40% of all tT$_{reg}$ cells. The RORγt-positive pT$_{reg}$ compartments in the colon and spleen were completely devoid of tisT$_{reg}$ST2 cells (Fig. 7c and Supplementary Fig. 18a). Importantly, tisT$_{reg}$ST2 cells located in the colon expressed higher levels of GATA-3 compared to pT$_{reg}$ and 'non-tisT$_{reg}$ST2' tT$_{reg}$ cells in the same tissue (Supplementary Fig. 18b). In summary, tisT$_{reg}$ST2 cells can be identified in virtually every peripheral tissue.

TisT$_{reg}$ST2 in the spleen

We investigated whether the small population of tisT$_{reg}$ST2 found in lymphatic organs resembled the tisT$_{reg}$ST2 pattern found in peripheral tissues. One of the important characteristics that we found in tisT$_{reg}$ST2 cells in skin and fat was the production of AREG and IL-10. To this end, we stimulated fat and spleen tisT$_{reg}$ST2 cells. About 80% of KLRG1$^+$ST2$^+$ tisT$_{reg}$ST2 cells from spleen produced AREG and showed elevated levels of IL-10 when compared to spleen KLRG1$^-$ST2$^-$ T$_{reg}$ cells, and thereby demonstrated a very similar effector profile comparable to tisT$_{reg}$ST2 cells isolated from fat tissue (Fig. 7d and Supplementary Fig. 19a, b). CD8$^+$ T cells and T$_{conv}$ did not produce AREG and IL-10 under the same conditions (Supplementary Fig. 19a). To further validate the similarities, we sorted the tisT$_{reg}$ST2 population from spleen and analyzed the characteristic tisT$_{reg}$ST2 profile, including additional genes that showed epigenetic changes in fat and skin T$_{reg}$ populations such as lamin A (*Lmna*) or oxysterol binding protein like 3 (*Osbpl3*). All analyzed genes were differentially expressed in the tisT$_{reg}$ST2 fraction from spleen compared to the global splenic T$_{reg}$ pool, including *Gata3, Rora* and *Irf4,* matching the profile of tisT$_{reg}$ST2 cells (Fig. 7e). Especially the effector molecules *Il10* and *Areg* were highly overrepresented with 65-fold and 16-fold difference, respectively, validating our functional protein expression data. To investigate whether the tisT$_{reg}$ST2 characteristic methylation changes could also be observed in the spleen counterpart, we sequenced PCR-based amplicons of bisulfite converted DNA based on DMRs identified in our whole-genome approach. Genes specifically demethylated in fat and skin tisT$_{reg}$ST2 cells, such as *Gata3* or *Klrg1*, were also hypomethylated in splenic tisT$_{reg}$ST2 cells, but not splenic Klrg1$^-$ST2$^-$ T$_{reg}$ cells (Fig. 7f).

To further dissect the tisT$_{reg}$ST2 cells found in lymphoid organs, we first looked at individual marker expression. Virtually all T$_{reg}$ cells in the skin expressed high levels of CD103, whereas less than 5% of fat-resident tisT$_{reg}$ST2 cells expressed this marker Analysis of tisT$_{reg}$ST2 cells from spleen showed that about 40% express CD103, indicating a heterogeneity of the tisT$_{reg}$ST2 population in this organ (Supplementary Fig. 19c). Induction of PPAR-γ in the fat tisT$_{reg}$ST2 population represented an additional functional tissue-based adaptation (Fig. 5c and Supplementary Fig. 20), comparable to demethylation and expression of the cannabinoid receptor gene *Gpr55* in skin T$_{reg}$ cells (Fig. 5d and Supplementary Fig. 20). When looking at the markers *Pparg* and *Gpr55,* which indicate tissue-restricted adaption of the tisT$_{reg}$ST2 pool in fat and skin, we found both to be highly over-represented in the spleen tisT$_{reg}$ST2 population (>30-fold) (Fig. 7g). To extend this analysis, we performed single cell RNA sequencing (scRNAseq) of tisT$_{reg}$ST2 cells isolated from spleen. As expected, all single cells expressed *Helios, Gata3* and *Klrg1.* In contrast to this, genes that were biased towards the skin-resident tisT$_{reg}$ST2 population, like *Itgae* (CD103), *Ahr* or *Gpr55* were only expressed in a fraction of individual cells, indicating the presence of subgroups of tisT$_{reg}$ST2 in the spleen, probably representing individual tissue characteristics (Fig. 7h). This suggests that fat and skin-resident T$_{reg}$ cells contain a recirculating fraction present in the lymphatic tisT$_{reg}$ST2 pool.

TisT$_{reg}$ST2 are distinct

To analyze whether tisT$_{reg}$ST2 are a distinct differentiation state of T$_{reg}$ cells, we first analyzed the presence of these cells over time. Our data showed that the fraction of tisT$_{reg}$ST2 cells among T$_{reg}$ cells in different tissues was stable over a time period of 5 to 25 weeks of age, indicating homeostasis of the tisT$_{reg}$ST2 compartment within tissues (Fig. 8a and Supplementary Fig. 21a, b). To understand the origin of tisT$_{reg}$ST2 cells, we studied whether lymphoid organ-derived, tisT$_{reg}$ST2-depleted T$_{reg}$ cells could be the precursor of tisT$_{reg}$ST2 cells found in tissues. To generate space in the T$_{reg}$ compartment, host T$_{reg}$ cells were depleted by injecting diphtheria toxin into *Foxp3*-DTR mice. Congenically marked KLRG1$^-$ST2$^-$ T$_{reg}$ cells were injected and skin and fat tissue was analyzed for the presence of tisT$_{reg}$ST2 cells after 10 days. These experiments showed that lymphoid organ T$_{reg}$ cells have the ability to seed the peripheral tissues and differentiate into tisT$_{reg}$ST2 cells (Fig. 8b).

To study the stability of already differentiated tisT$_{reg}$ST2 cells, we cultured fat-derived tisT$_{reg}$ST2 under well-defined conditions with anti-CD3+CD28 beads and IL-2 for six days *in vitro.* TisT$_{reg}$ST2 cells showed a very stable expression pattern of characteristic markers such as *Il1rl1, Pparg, Osbpl3, Batf, Tigit, Gata3,* and *Klrg1* comparable to freshly isolated tisT$_{reg}$ST2 from fat. In parallel, cultivated 'non-tisT$_{reg}$ST2' T$_{reg}$ cells did not upregulate these characteristic genes, indicating that expression of these genes is not a mere function of T$_{reg}$ activation and that the tisT$_{reg}$ST2 program is not a temporary state, but a stable program (Fig. 8c).

In order to identify an essential transcription regulator for tisT$_{reg}$ST2 cells, we focused on BATF. As described earlier, our data showed that *Batf* is over-expressed in tisT$_{reg}$ST2 cells, its gene locus is heavily hypomethylated in tissue T$_{reg}$ cells from fat and skin, and we identified an enrichment of BATF DNA binding motifs in regions of genes that were

specifically hypomethylated in tissue T_{reg} cells. Indeed, BATF deficient mice showed severely reduced numbers of tisT_{reg}ST2 in all organs analyzed, including skin, fat, lung, bone marrow, LN and spleen, while numbers of other T_{reg} cells in the same tissues were not reduced. These data show that BATF is an essential transcriptional regulator of tisT_{reg}ST2 cells (Fig. 8d).

As tisT_{reg}ST2 cells are characterized by the expression of ST2, we wanted to understand if IL-33 could act as a growth factor amplifying the tisT_{reg}ST2 pool *in-vivo*. Administration of recombinant IL-33 substantially expanded the tisT_{reg}ST2 population in all organs tested. Numbers of tisT_{reg}ST2 cells were increased by 10-fold in fat, 5-fold in skin, 13-fold in liver, and 60-fold in lung tissue (Fig. 8e). This expansion did not change the identity, as GATA-3 was still over-expressed in expanded cells as compared to 'non-tisT_{reg}ST2' T_{reg} cells isolated from the same organs (Supplementary Fig. 21c). Collectively, these data showed that tisT_{reg}ST2 cells are a distinct state. They require the transcription factor BATF, and can be expanded via IL-33 signaling *in situ*.

Discussion

The present study provides evidence that tissue T_{reg} cells undergo extensive epigenetic reprogramming. Changes in the methylome can be used to determine the underlying functional programs. The similarities in the epigenetic landscape between fat- and skin-resident T_{reg} cells allowed us to identify a common tissue T_{reg} population, characterized by the expression of KLRG1 and ST2, a T_H2-like program, and the production of tissue regenerative factors.

Classically, T_{reg} cells were viewed as regulators of other immune cells. With the characterization of fat T_{reg} cells, this notion has been extended to a second critical function, supporting organ homeostasis3. In visceral adipose tissue, about 80-90% of T_{reg} cells represent the here described tisT_{reg}ST2 phenotype. In skin, this number was somewhat lower at about 50-60% of T_{reg} cells, and in lung and liver between 10-20%. These findings explain why fat and skin-resident T_{reg} cells shared a closer relation in the DNA methylome analysis as compared to liver T_{reg} cells. It is intriguing that this T_H2-biased tisT_{reg}ST2 subset is present in virtually every organ. ST2, as well as the transcription factors BATF and IRF4, were shown to be required for fat T_{reg} cell differentiation6. Based on our data, we could show that BATF and IL-33 are not just important for fat T_{reg} cells, but for tisT_{reg}ST2 in all tissues, extending the perspective from an adipose centered view to a global one.

Our data also show that tissue T_{reg} cells integrate epigenetic changes from multiple differentiation steps. The first specific epigenetic reprogramming occurs during thymic differentiation and stabilizes the universal T_{reg} identity13. The second line of epigenetic modifications solidifies the functional 'tisT_{reg}ST2' specialization via selective hypomethylation of a signature that includes more than 100 genes. Thereby, the tisT_{reg}ST2 population acquires a unique reprogramming landscape. On top of this tisT_{reg}ST2 specialization program, we find tissue-specific epigenetic reprogramming. In the fat T_{reg} population, we identified, among others, methylation differences in the *Pparg* gene. In addition, skin T_{reg} cells revealed several interesting epigenetic differences, where *Ahr* and

Gpr55 could be of specific relevance. Ahr signaling is important for immune cells and their function at barrier organs such as the skin[24]. Grp55, as a cannabinoid receptor, is associated with algesia linked to inflammatory and neuropathic pain, and could enable nociception by skin T_{reg} cells in an organ with a strong pain perception[25, 26].

Where does the epigenetic reprogramming take place? Are most organs independently able to induce the common $tisT_{reg}ST2$ program, and, in addition, add organ specific flavors? Alternatively, one or very few organs could induce the $tisT_{reg}ST2$ reprogramming and, by circulation, cells reach the individual tissues where they further specialize. In the latter, the fat tissue could be such a candidate as the vast majority of T_{reg} cells in this tissue are $tisT_{reg}ST2$ reprogrammed. However, parabiosis experiments detected only a low degree of chimerism in the fat tissue T_{reg} compartment, indicating little exchange of tissue T_{reg} cells via the circulation[27]. It is also possible that $tisT_{reg}ST2$ cells found in spleen or LN represent a backup population that can quickly be recruited to support distressed organ homeostasis. In addition, it is very unlikely that local conversion from T_{conv} into T_{reg} is responsible since our data show that $tisT_{reg}ST2$ are only present in the tT_{reg}, but not pT_{reg} fraction, and are demethylated at the *Ikzf2* locus.

$TisT_{reg}ST2$ do not express the T_H2-associated cytokines IL-4 and IL-13, but express IL-10 and AREG. *Areg* expression could presumably be induced by ST2 signaling, and was shown to be important for tissue repair in the lung[8]. The $tisT_{reg}ST2$ population could therefore represent the prototype of tissue-repair prone T_{reg} cells mediating tissue homeostasis by using the tissue regenerative factor AREG. This could have clinical implications in the adoptive transfer of T_{reg} cells to treat autoimmune and graft versus host diseases[28]. Deliberate type-2 conditioning by IL-4 and IL-33 during the *in vitro* expansion of blood-derived T_{reg} cells might amplify their therapeutic potential, especially in respect to supporting tissue repair functions. Indeed, ST2-dependent protective T_{reg} functions could be demonstrated in the colon and adipose tissue[6, 29].

As *Foxp3* demethylation is used as a diagnostic marker to detect T_{reg} cells[12, 30], peripheral reprogramming events can be used to study the functional capacity of T_{reg} cells. We identified thousands of DMRs with single CpG resolution, characterizing the universal T_{reg} identity and the peripheral reprogramming. These differences will allow the design of diagnostic probes for amplicon-based sequencing to follow the origin and cell fate of T_{reg} cells in various pathological conditions. Indeed, the here described difference in methylation of *Ikzf2* between tT_{reg} and RORγt-positive pT_{reg} cells is such an example. Analyzing the epigenetic landscape is more than a complementary approach to describe T_{reg} cells; it will help to define T_{reg} cell identities and the permanent underlying molecular programs.

Data availability Statement

The source data are deposited as Fastq files from all TWGBS, RNA-Seq, and single-cell RNA-Seq in the European Nucleotide Archive (ENA) with the accession code PRJEB14591 (http://www.ebi.ac.uk/ena/data/view/PRJEB14591).

Online Methods

Mice

Wildtype C57BL/6, congenic B6.SJL-Ptprc^{a}Pepc^b/BoyCrl (CD45.1$^+$), congenic B6.PL-Thy1^a/CyJ (CD90.1$^+$), and *Nr4a1*-GFP (C57BL/6-Tg(Nr4a1-eGFP/cre)820Khog/J; Jackson Stock Number: 016617)[23] mice were obtained from Charles River Breeding Laboratories (Wilmington, MA, USA) or the Jackson Laboratory (Bar Harbor, ME, USA). B6N.129(Cg)-Foxp3^{tm3Ayr} mice (Foxp3.IRES-DTR/GFP)[31] were bred to CD45.1$^+$ or CD90.1$^+$ mice in the animal facility of the German Cancer Research Center (DKFZ). B6N.129(Cg)-Foxp3^{tm3Ayr} and B6.129(Cg)-Foxp3$^{tm4(YFP/cre)Ayr}$/J, Jackson (Foxp3.IRES-YFP/Cre)[32] were used to sort YFP or GFP positive T$_{reg}$ cells.

All animals used in this study were male and between 15 and 30 weeks old, unless otherwise indicated. Animals were housed under specific pathogen-free conditions at the DKFZ animal care facility, and the governmental committee for animal experimentation (Regierungspräsidium Karlsruhe, Germany) approved all experiments involving animals.

Tissue digestion for flow sorting of cells

For cell isolation, we used *Foxp3*^{GFP} or *Foxp3*^{YFP} reporter mice (Foxp3.IRES-DTR/GFP or Foxp3.IRES-YFP/Cre). T cells were extracted from gonadal visceral adipose tissue (called fat in the study), skin, liver, and inguinal lymph nodes. For lymph nodes, single-cell suspensions were established and red blood cells were lysed. Epididymal visceral abdominal tissue was first mechanically dissected followed by digestion with a buffer containing collagenase II (1 mg/mL), BSA (20 mg/mL) and DNAse (20 µg/mL) for 45 minutes at 37°C in a slow shaking waterbath. Afterwards, the cell suspension was shortly incubated with 0.5 Mol EDTA-H$_2$O, pelleted and further filtered. To isolate cells from skin tissue, back skin area of sacrificed skin was depilated by shaving and hair removal cream, followed by mechanically dissection and digest using a buffer containing collagenase IV (4 mg/mL), FCS (2% vol/vol), and DNAse (10 µg/mL) for 45 minutes at 37°C in a slow shaking waterbath, followed by filtration steps. Liver tissue cells were isolated from perfused animals, mechanically dissected and treated with digestion buffer containing collagenase II (1 mg/mL), BSA (5 mg/mL), and DNAse (20 µg/mL) for 45 minutes at 37°C in a slow-shaking waterbath followed by a Percoll gradient centrifugation step and filtrations. Cells from lung were isolated from perfused animals following a digestion step similar to fat cells (collagenase II (1 mg/mL), BSA (20 mg/mL) and DNAse (20 µg/mL)).

After purification, cells were filtered through a 70µM filter mesh and either stained for flow cytometry-based isolation of target cells or pre-enriched with anti-CD25 magnetic beads followed by column-based isolation. Cells were stained with antibodies as indicated in the next paragraph. Live/dead cell exclusion was performed with a fixable live/dead stain.

Flow sorting and DNA/RNA purification

Stained cells were twice sorted, first "pre-sorted" with moderate purity settings on a BD ARIA II or III cell-sorting machine (4-way sort, "enrich mode") into flow buffer. Then, cells were re-acquired and sorted again with high purity settings (4-way sort, "4-way purity

mode") directly into either DNA or RNA lysis buffer. Aliquots were sorted into flow buffer for post-sort purity controls, as illustrated in Supplementary Figure 1. T_{reg} cells from tissues were defined as CD3$^+$CD4$^+$CD8$^-$CD45$^+$CD25$^+$Foxp3(GFP)$^+$ population, while T_{conv} cells were sorted as CD3$^+$CD4$^+$CD8$^-$CD45$^+$Foxp3(GFP)$^-$ or as CD3$^+$CD4$^+$CD8$^-$CD19$^-$ CD45$^+$CD90.1$^+$Foxp3(GFP)$^-$ population. Spleen pT$_{reg}$ were defined as CD4$^+$CD8$^-$CD19$^-$ MHCII$^-$CD25$^+$Foxp3(GFP)$^+$HELIOS$^-$RORγt $^+$, while spleen tT$_{reg}$ were defined as CD4$^+$CD8$^-$CD19$^-$MHCII$^-$CD25$^+$Foxp3(GFP)$^+$HELIOS$^+$RORγt$^-$. TisT$_{reg}$ST2 cells were defined as CD3$^+$CD4$^+$CD8$^-$CD45$^+$CD25$^+$Foxp3(GFP)$^+$KLRG1$^+$ST2$^+$ population. In the thymus, double negative 1 (DN1) thymocytes were sorted as CD4$^-$CD8$^-$CD25$^-$CD44$^+$, early thymic T_{reg} precursors as CD4$^+$CD8$^-$TCRb$^+$CD69$^+$CD25$^-$Foxp3(GFP)$^-$, late thymic T_{reg} precursors as CD4$^+$CD8$^-$TCRb$^+$ CD69$^+$CD25$^+$Foxp3(GFP)$^-$, and mature thymus T_{reg} cells as CD4$^+$CD8$^-$TCRb$^+$CD69$^-$CD25$^+$Foxp3(GFP)$^+$. From spleen and lymph nodes, we isolated CD44-positive T_{reg} cells (CD4$^+$CD8$^-$CD44$^+$CD25$^+$CD25$^+$ Foxp3(GFP)$^+$), CD44-positive T_{conv} cells (CD4$^+$CD8$^-$CD44$^+$CD25$^-$ Foxp3(GFP)$^-$), naive T_{reg} cells (CD4$^+$CD8$^-$CD44$^-$CD25$^+$ Foxp3(GFP)$^+$), naive T_{conv} cells (CD4$^+$CD8$^-$CD44$^-$CD25$^-$Foxp3(GFP)$^-$), *in vitro* induced T_{reg} cells (CD4$^+$CD8$^-$CD25$^+$Foxp3(GFP)$^+$) and *in vitro* activated T_{conv} cells (CD4$^+$CD8$^-$CD25$^+$Foxp3(GFP)$^-$). In addition, we sorted Foxp3^{high}, Foxp3^{intermediate}, and Foxp3^{low} expressing T_{reg} cells (CD3$^+$CD4$^+$CD8$^-$CD19$^-$CD25$^+$Foxp3(GFP)$^{high/int/low}$), CD25^{negative} Foxp3-expressing cells (CD3$^+$CD4$^+$CD8$^-$CD19$^-$CD25$^-$Foxp3(GFP)$^+$) and T_{conv} cells (CD3$^+$CD4$^+$CD8$^-$CD19$^-$CD25$^-$Foxp3(GFP)$^-$) from spleen and lymph nodes. Genomic DNA was isolated using a gDNA Microprep Kit (Zymo Research) and concentrations were measured with a Qubit® fluorometer. RNA was isolated with the RNEasy mini kit (Quiagen) and concentration was determined with a 2100 Bioanalyzer instrument (Agilent technologies).

Tagmentation-based whole genome bisulfite sequencing (TWGBS)

We applied TWGBS for very low input DNA amounts according to 33 with some modifications. Double stranded pre-adapters consisted of oligo Tn5MErev ([phos]CTGTCTCTTATACACATCT) and either methylated oligo Tn5mC-Apt1 (TcGTcGGcAGcGTcAGATGTGTATAAGAGAcAG) or methylated oligo Tn5mC-Apt2 (GTcTcGTGGGcTcGGAGATGTGTATAAGAGAcAG); the lower case c base indicates 5-methyl cytosine. Pre-adapters were combined at 1:1 ratio to generate a 10 µM load adapter mixture. The transposome was assembled by mixing 12 µL load adapter and 10µL Ez-Tn5 transposase (Epicentre). About 10 ng genomic DNA and 5pg unmethylated λ DNA were used for tagmentation with 1 µl transposome. Tagmented DNA was purified with AmPure beads (Beckman Coulter) and repaired with Bst DNA polymerase (NEB) and 5mC-dNTP mix (Zymo). After a further bead purification, the DNA was bisulfite-converted with the EZ DNA methylation kit (Zymo) according to the manufacturer's instructions. From each converted DNA sample, four differently barcoded sequencing libraries were generated by PCR (95°C, 3 min; 12 cycles 95°C, 20 sec; 62°C, 15 sec; 72°C, 40 sec) using Kapa 2G Robust HotStart ReadyMix (Kapa Biosystems), SYBRGreen reagent (Life Technologies), primer Tn5mCP1 (AATGATACGGCGACCACCGAGATCTACACTCGTCGGCAGCGTC) and barcoded Tn5mC reverse primers (CAAGCAGAAGACGGCATACGAGAT (- 8 bases barcode-) GTCTCGTGGGCTCGG). Library pools were 100bp paired-end sequenced using Illumina HiSeq 2000.

Ultra-low RNA Sequencing

cDNA was generated and amplified using 0.8 ng of total RNA and SMARTer Ultra Low Input RNA for Illumina Sequencing - HV (Clontech Laboratories, Inc.) according to the manufacturer's protocol. Then, sequencing libraries were prepared using the NEXT ChIP-Seq Library Prep Master Mix Set for Illumina (New England Biolabs) according to the manufacturer's instructions with the following modifications: The adapter-ligated double-stranded cDNA (10μl) was amplified using NEBNext Multiplex Oligos for Illumina (New England Biolabs, 25 μM primers), NEBNext High-Fidelity 2x PCR Master Mix (New England Biolabs) and 15 cycles of PCR. Final libraries were validated using Agilent 2100 Bioanalyzer (Agilent Technologies) and Qubit flourometer (Invitrogen), normalized and pooled in equimolar ratios. 50bp single-read sequencing was performed on the Illumina HiSeq 2000 v4 according to the manufacturer's protocol.

Read pair preprocessing of TWGBS data

To determine whether read pairs originated from the original strand in the genome (C converted to T in read 1 and G converted to A in read 2 during bisulfite treatment) or the reverse complementary (G converted to A in read 1 and C converted to T in read 2), we performed the following preprocessing before the alignment: Since the Cs in CpG sites are mainly methylated thus unconverted, they were excluded from the analysis, i.e., CpG, TpG, GpC and GpT dinucleotides were masked. For each read in every read pair, we than calculated the base ratios T/C and A/G denoted as $R1_{T/C}$, $R1_{A/G}$ and $R2_{T/C}$, $R2_{A/G}$. We then compared these ratios between the first and second read in a read pair to determine if they are assigned in (R1-R2) or (R2-R1) order or cannot be assigned to any order. The following rules were applied: (1) Read pairs where the condition $R1_{T/C} > R2_{T/C}$ and $R2_{A/G} > R1_{A/G}$ held true, we assumed the read pair came from the original strand and assigned them the (R1-R2) read order. (2) Read pairs where the conditions $R1_{T/C} < R2_{T/C}$ and $R2_{A/G} < R1_{A/G}$ were met, we assumed the read pair came from the reverse complementary strand and read order (R2-R1) was assigned. (3) Read pairs that did not meet one of the conditions above were ambiguous thus disregarded from the analysis.

Mapping of whole-genome bisulfite sequencing data and methylation calling

The TWGBS data were processed as described in 34: The mm10 reference genome (GRCm38.73) was transformed *in silico* for both the top strand (C to T) and bottom strand (G to A) using MethylCtools35. Before alignment, adapter sequences were trimmed using SeqPrep (https://github.com/jstjohn/SeqPrep). The first read in each read pair was then C-to-T converted and the second read in the pair was G-to-A converted. The converted reads were aligned to a combined reference of the transformed top (C to T) and bottom (G to A) strands using BWA (bwa-0.6.2-tpx)36 with default parameters, yet disabling the quality threshold for read trimming (-q) of 20 and the Smith-Waterman for the unmapped mate (-s). After alignment, reads were converted back to the original states, and reads mapped to the antisense strand of the respective reference were removed. Duplicate reads were marked, and the complexity determined using Picard MarkDuplicates (http://picard.sourceforge.net/). Reads with alignment scores less than 1 were filtered before subsequent analysis. Total genome coverage was calculated using the total number of bases aligned from uniquely

mapped reads over the total number of mappable bases in the genome. At each cytosine position, reads that maintain the cytosine status were considered methylated, and the reads that have cytosine converted to thymine were considered unmethylated. Only bases with Phred-scaled quality score of 20 were considered. In addition, the 5 bp at the two ends of the reads were excluded from methylation calling according to M-bias plot quality control. For the TWGBS libraries, the first 9 bp of the second read and the last 9 bp before the adaptor of the first read were excluded from methylation calling.

Calling of differentially-methylated regions (DMRs)

The raw counts of methylated and unmethylated reads for each CpG site from different libraries were merged for each replicate. BSmooth37 was used (default parameters, version 1.2.0) to call differentially methylated regions (DMRs) for all possible ten pairwise tissue-tissue comparisons. Each comparison contained three replicates in each group (3vs3 comparison). To account for possible false positive DMRs reported by BSmooth, due to smoothing in non-informative / low coverage regions, we applied additional filtering procedures. On autosomes we selected for DMRs which had a mean CpG-coverage per DMR greater or equal to five in all six replicates in a particular comparison based on raw read counts. We applied a paired Wilcoxon test on each DMR based on the beta-values of the six replicates. To correct for multiple testing, the resulting p-values have been Benjamini-Hochberg corrected and only DMRs with a p-value lower or equal 0.05 were selected. Due to the fact that all animals in this study were male mice, we expected lower coverage for the sex chromosomes. On allosomes, we pooled the raw counts from the three replicates in each group and selected DMRs with a coverage of >10. All DMRs from all chromosomes were filtered requiring a minimal mean methylation value difference of 0.3.

Principal Component Analysis (PCA) and hierarchical clustering on DMRs

The methylation values of called DMRs from all ten possible tissue-tissue comparisons were joined into a single matrix. Duplicate DMRs (exact same start and end bp position) were eliminated from the matrix. A PCA on all replicates using R (3.1.2) and prcomp was performed. A complete-linkage clustering was performed allowing for clustering of rows (DMRs) and columns (replicates) using R (3.1.2) and pheatmap.

Identification of promoter, intragenic, intergenic regions and TSS

Unique DMRs from all ten comparisons have been annotated (bedtools-2.24.0 closest38) using parameters -d to report distance and -t "first" to handle ties. We used *RefSeq* September 2013 version and defined promoters as 2000 bp upstream if the gene is located on the plus strand and 500 downstream if located on minus strand. The TSS was defined as the first bp downstream if on plus strand and the first bp upstream if on minus strand. Whole-genome data were visualized in a circos plot as described in39.

Calculation of average distance of DMRs from TSS

To calculate the distance of DMRs from the transcription start site (TSS), we first normalized all DMRs to the same DNA strand, subtracted the mean DMR genomic localization from the TSS coordinates, grouped the results into 500 bp clusters from -10000

to +10000 bp, and quantified the number of DMRs in each cluster. DMRs with more than 10,000 bp distance from the respective TSS were disregarded.

Pearson Correlation between gene expression and methylation

For this analysis, we included DMRs, which were intragenic or within 5kb up/downstream of the nearest gene according to RefSeq annotation. Methylation values and RPKM values were associated with each other using the RefSeq gene identifiers. For each gene we applied a correlation test using Pearson correlation with a cutoff of less or equal -0.7 or greater/equal 0.7 allowing for negative as well as positive correlation.

Hierarchical clustering of DMRs and RNA data

From the DMRs with an absolute Pearson correlation coefficient of bigger or equal 0.7, we created a new matrix of methylation values including all replicates. We applied complete-linkage hierarchical clustering to generate a heatmap using R (v3.1.2) and pheatmap. We further applied R (v3.1.2) and mclust(v5.1)[1] to estimate the number of clusters using parameters: mclust(…, G=1:20). The resulting number of clusters was four and we cut the resulting tree for the DMRs from the complete-linkage using cutree (…, k=4) into four different clusters.

Motif analysis

For each of the four identified clusters we merged overlapping DMRs (bedtools-2.24.0 merge) to avoid possible bias by overrepresentation and extracted the corresponding genomic DNA sequences (bedtools-2.24.0 fasta). All genomic regions in the four clusters where scored with the JASPAR motif library40 using the total binding affinity (TBA) score. Briefly, the TBA score is computed for each genomic region by summing for each position the maximum PWM score between the plus and minus strand41. Then, for each PWM, the regions were ranked according to their TBA score in decreasing order. For each PWM, we determined the recovery curve for the regions in a specific cluster, and the area under the curve (AUC) was computed over the first 300 regions. AUC values were converted into a z-score by computing the mean and standard deviation of the AUC over 1000 randomizations of the ranks. For each set of regions inside a cluster, the z-scores for the PWMs were represented as a heatmap. Only motifs which have an absolute z-score above 3 in one of the clusters are displayed.

Mapping of RNA sequencing data, statistical evaluation and plotting

For all samples, low quality bases were removed with Fastq_quality_filter from the FASTX Toolkit 0.0.13 (http://hannonlab.cshl.edu/fastx_toolkit/index.html) with 90 percent of the read needing a quality phred score > 20. Homertools 4.742 were used for PolyA-tail trimming, and reads with a length < 17 were removed. PicardTools 1.78 (https://broadinstitute.github.io/picard/) were used to compute the quality metrics with CollectRNASeqMetrics. With STAR 2.343, the filtered reads were mapped against mouse genome 38 using default parameters. Count data were generated using *HTSeq*44 for the genes. For the comparison with DESeq245, the input tables containing the replicates for groups to compare were created by a custom perl script. For *DESeq2*,

DESeqDataSetFromMatrix was applied, followed by *estimateSizeFactors*, *estimateDispersions*, and *nbinomWald testing*. The result tables were annotated with gene information (gene symbol, gene type) derived from the gencode.vM8.gtf file. For the RPKM table of non-coding RNAs, a custom perl script separated non-coding RNA genes from protein coding genes and calculated their RPKM values from the *HTSeq* count values. Mapping filtered reads against protein coding transcripts using a custom pipeline generated the RPKM table of the protein coding genes. These genes (status "KNOWN") were extracted from the Mouse EnsEMBL (Rel. 80) database. Mapping was carried out with bowtie2 version 2.2.446 against union mouse genes: every gene is represented by a union of all its transcripts (exons). The count values (RPKM and raw counts) were calculated by running CoverageBed from Bedtools v2.17.038 of the mapped reads together with a specific mouse annotation file for protein coding genes (based on Ensembl 80) in gtf format and parsing the output with custom perl scripts. MA plots were generated as described in47. For hierarchical clustering of RNA data a complete-linkage clustering was performed using R (3.1.2) and pheatmap.

Unsupervised clustering, computing of heatmaps, methylation plotter

Unsupervised hierarchical clustering was performed with Gene Pattern software/hierarchical clustering tool (http://genepattern.broadinstitute.org/). Column and row distance measure were set to Pearson correlation with pair-wise average linkage clustering. No normalizations or transformations have been performed. Heatmaps were generated with gene pattern software/heatmap viewer. Methylation plots (Figure 3C, Supplementary Figure 13c) were generated with methylation plotter48.

Isolation of RNA and reverse transcription followed by qPCR

Sorted cell populations were lysed and RNA was isolated using the RNeasy Mini Kit (Quiagen). Synthesis of cDNA was performed with SuperScript Reverse Transcriptase II and oligo(dT) primers (both Life Technologies) according to manufacturer's instructions. Real-time PCR was performed using a ViiA7 instrument (Applied Biosystems) and Taqman master mix (Applied Biosystems). Gene expression values were normalized to housekeeping genes (*Hprt*).

Purification and bisulfite conversion of genomic DNA

Sorted cell populations were resuspended in PBS and genomic DNA was purified according to manufacturers guidelines using the DNEasy Blood and Tissue kit (Quiagen). For pT_{reg} and tT_{reg} isolation, cells were fixed and stained with the Foxp3 Fix/perm buffer set (eBiosciences) according to manufacturer's instruction. Cells were then sorted into lysis buffer included in the QIAamp DNA micro kit (Quiagen). Reverse cross-linking of gDNA was performed for one hour at 56°C and one hour at 90°C, followed by gDNA isolation. DNA purity and concentration was measured with a NanoDrop or Qubit photometer. Bisulfite-conversion was performed using the EpiTect Bisulfite Conversion Kit (Quiagen) and converted DNA was used immediately after purification or aliquoted and stored at -20°C.

Computation and testing of bisulfite-DNA primers

Genomic DNA was *in-silico* bisulfite-converted using the Bisulfite Primer Seeker software (http://www.zymoresearch.com/tools/bisulfite-primer-seeker). Primer sequences were calculated based on manufacturers recommendations. Primer pairs were tested on bisulfite-converted genomic DNA to determine optimal annealing temperature range and cycle number for each specific reaction. Once parameters were optimized, adaptor sequences for 454 sequencing and barcodes to distinguish individual samples were attached to each primer pair sequence and synthesized. Alternatively, Illumina adapter sequences were attached to primer pairs for Illumina sequencing. Based on optimal annealing temperature and PCR cycle number, primers were used to generate PCR amplicons from bisulfite-converted DNA for each cell type tested. An overview of primers used for our sequencing experiments is listed in the key resources table. Once genomic DNA had been bisulfite-converted, PCR reactions with bisulfite-specific primers were performed. PCR amplicons were separated from primer dimers on 1%-2% agarose gels and visualized using ethidium bromide. Specific bands were excised under UV light exposure and DNA amplicons were purified using a Quick Gel Extraction Kit (Life Technologies). Equimolar amounts of amplicons were combined and processed on a GS Junior Sequencer (Roche). Sequence reads were aligned to the bisulfite-converted mouse genome and methylation levels were visualized in heat maps. Alternatively, Illumina-tagged amplicons were processed on an Illumina MiSeq V3 machine with Paired-End 300bp or Paired-End 250bp settings. Raw data were aligned to the mouse genome and CpG methylation was calculated. Detailed genomic positions of amplicon data are either labeled in the respective graph or depicted here: *Foxp3* R3 (Figure 3g; CG#1: 7,583,950; CG#2: 7,583,986; CG#3: 7,584,002; CG#4: 7,584,036; CG#5: 7,584,063; CG#6: 7,583,950), *Ikzf2* (Figure 3g; CG#1: 69,670,284; CG#2: 69,670,291; CG#3: 69,670,370; CG#4: 69,670,377; CG#5: 69,670,385), *Il2ra* (Figure 3g; CG#1: 11,645,653; CG#2: 11,645,705; CG#3: 11,645,718; CG#4: 11,645,738), *Ctla4* (Figure 3g; CG#1: 60,912,472; CG#2: 60,912,521; CG#3: 60,912,536; CG#4: 60,912,573), *Gata3* (Figure 7f; CG#1: 9,868,708; CG#2: 9,868,720; CG#3: 9,868,768; CG#4: 9,868,789; CG#5: 9,868,820; CG#6: 9,868,844; CG#7: 9,868,855; CG#8: 9,868,858; CG#9: 9,868,883; CG#10: 9,868,948; CG#12: 9,868,958), *Lef1* (Figure 7f; CG#1: 131,116,109; CG#2: 131,116,113; CG#3: 131,116,152; CG#4: 131,116,173; CG#5: 131,116,187; CG#6: 131,116,191; CG#7: 131,116,196; CG#8: 131,116,257; CG#9: 131,116,288; CG#10: 131,116,302; CG#11: 131,116,327, CG#12: 131,116,356).

Flow cytometry

Tissues were isolated and digested as described previously. Single-cell suspension were stained with surface antibodies for 30 minutes at 4°C. If applicable, cells were fixed and permeabilized with the Foxp3 Fix/Perm Buffer Set (eBiosciences) for one hour at RT, followed by intracellular staining. Antibodies used for flow cytometry experiments were conjugated to either Brilliant Violet 411, eFluor 506, Brilliant Violet 605, Brilliant Violet 711, Brilliant UV 395, Brilliant UV 737, PE, AF488/FITC, PE-Cy7, AF647/APC, APC-Cy7, or PerCP-Cy5.5 and are listed in key resources table. Following life dead exclusion dyes were used: Fixable viability dye eFluor506 and eFluor780 (eBiosciences). If applicable, biotin-labeled primary antibodies were stained with fluorchrome-labeled secondary antibodies for 30 minutes at 4°C. Primary Lef1 and Tcf7 antibodies were stained

with an anti-rabbit-IgG AF 647-conjugated secondary antibody. Areg and IL-10 stainings were performed as intracellular staining. Samples were acquired on a BD LSRII or a LSR Fortessa 5-laser flow cytometer. Biological replicates were measured separately. Data were analyzed with FlowJo software, and, in figures, concatenated files of biological replicates are shown. Concatenation was performed with FCS Concat (Cytobank).

IL-4 co-culture of T_{reg} cells; iT_{reg} cell induction

Spleen and lymph nodes from Foxp3.IRES-DTR/GFP animals were harvested. T_{reg} cells were pre-enriched with CD25 bead-based positive selection, while T_{conv} cells were pre-enriched with CD4 bead-based positive selection (autoMACS Pro Separator, Miltenyi Biotec). Pre-enriched T_{reg} and T_{conv} cells were sorted by FACS to isolate pure KLRG1⁻ ST2⁻ populations from both cell types. Cells were then seeded at 100,000 cells per well with anti-CD3/CD28 beads (Life technologies), IL-12-23p40 blocking mAb, IFNγ blocking mAb, murine IL-2 (Peprotech) and escalating doses of murine IL-4 (Peprotech). Cells were incubated for six days at 37°C and afterwards lysed for immediate RNA isolation, cDNA synthesis and real-time PCR, as described previously.

To generate *in vitro* induced T_{reg} cells (iT_{reg} cells), T_{conv} cells were pre-enriched by negative selection with CD8, CD11b, CD11c, CD19, CD25, and CD49b antibodies and magnetic beads. Afterwards, cells were treated with murine TGF-β (Peprotech) and incubated with CD3/28 microbeads for six days at 37°C.

Measurement of IL-10 and AREG production in spleen T cells

Spleens from Foxp3.IRES-DTR/GFP animals were harvested. Single-cell suspensions were established and red blood cells lysed. Afterwards, cells were treated with 1X PMA and Ionomycin cell stimulation cocktail plus transport inhibitor (eBiosciences) or 1X transport inhibitor only. In addition, all samples were subjected to metalloproteinase inhibitor treatment with 10 μM Marimastat (Sigma). Cells were stimulated for 4 hours at 37°C, followed by surface staining, fixation with the Foxp3 Fix/Perm Buffer Set (eBiosciences), and subsequent measurement via flow cytometry.

Single-cell RNA sequencing

To generate the single-cell RNA-sequencing (scRNA-seq) data, we isolated tisT_{reg}ST2 from pooled spleens, followed by cell capture, cDNA synthesis and amplification on the C1 Single-Cell Auto Prep IFC (Fluidigm). In two separate runs, a total of 127 cells corresponded to single cells (as confirmed by visual inspection of the captured cells). Sequencing libraries were produced with the Illumina Nextera XT kit according to an adopted Fluidigm protocol. All single cells from one C1 run (about 65 cells on average) were pooled and sequenced 1x50 bp reads on an Illumina HiSeq 2000 machine. For each cell, reads were aligned to the murine genome (ERCC sequences concatenated to GRCm38.p4 version 84) with STAR43 version 2.5. On average 70 % of the reads were uniquely mapped. Raw counts were quantified from position-sorted alignment files with HTSeq-count44 using mode 'union' and default quality thresholds of 10. In order to remove bias introduced by low quality data we performed the quality control using the scater package as described in49. Cells were removed as low quality if one or more of the

following conditions were met: low library size (0 cells), low number of captured transcripts (2 cells), exceeding mitochondrial content (11 cells) or exceeding ERCC sequences (13 cells). In total 101 cells remained for further analysis. The scran package49 was used to normalize raw counts with deconvolution and to identify HVGs, (with ERCC-fit, span=0.2, FDR=0.05).

Stability of tisT$_{reg}$ST2 *in vitro*

KLRG1$^+$ST2$^+$ tisTregST2 from fat were isolated by FACS as described previously. In addition, KLRG1-ST2- T$_{reg}$ from spleen were isolated by FACS. Samples were frozen for 0h timepoint analysis or tisT$_{reg}$ST2 and KLRG1-ST2- cells were incubated with CD3/CD28 microbeads (Dynabeads, Thermo Fisher Scientific) and 5000 U/mL IL-2 for six days at 37°C. Then, cells were lysed and RNA was isolated. Gene expression was determined by qPCR with Taqman probes as described previously. Four biological replicates have been performed.

Transfer of congenically-labeled KLRG1$^-$ST2$^-$ T$_{reg}$ cells into T$_{reg}$-depleted hosts

T$_{reg}$ cells were isolated from CD45.2$^+$ Foxp3$^{YFP, Cre}$ animals with CD25 bead-based pre-enrichment and a reduced staining protocol (CD8$^-$CD19$^-$CD25$^+$Foxp3-YFP$^+$KLRG1$^-$ST2$^-$). Cells were then injected into CD45.1$^+$ recipient animals intravenously. Control animals received PBS injections. In addition, all recipient animals were treated with peritoneal injections of Diptheria Toxin (DT) to eliminate all host-resident T$_{reg}$ cells. DT injections were repeated after 24 hours. Animals were analyzed ten days after T$_{reg}$/PBS injections have been performed. Four recipient animals were treated with T$_{reg}$ injections from five donor animals. Four recipients were treated with PBS injections. Two animals were used as untreated controls to ensure proper gating.

Expansion of tisT$_{reg}$ST2 with IL-33 *in vitro*

Foxp3^{GFP} animals were injected with either 5µg recombinant murine IL-33 or PBS into the peritoneum on day 1 and day 3 (Biolegend). On day six, mice were sacrificed and frequency and percentage of tisT$_{reg}$ST2 in tissues was evaluated by flow cytometry.

Bioinformatics and statistical analysis

Massive parallel sequencing data were statistically tested as described above, and these statistical values were used in Fig. 2a (MA plots), 5c (*Pparg*), 5d (*Gpr55*), 6b (*Irf4, Rora, Batf*), 6d (*Il10*), and Supplementary Fig. 12, 13a, 13b, 15a, 15b and 20 with n=3 for all comparisons. Data based on flow cytometry or real-time PCR were tested with unpaired two-tailed student's t tests in Fig. 6e (n=4), 7c (n=10), 7d+g (n=4), 8d (n=6-10), 8e (n=4) and in Supplementary Fig. 18a (n=10), 19a (n=4), 19b (n=4), 21b (n=5), 21c (n=4). One-way ANOVA with Bonferoni post-test was used in Figures 5a (n=4-19), 5d (CD103, n=9), 6b (GATA-3, n=4-19), 6d (ST2, n=4), and Supplementary Fig. 13c (n=4-19), 14b (n=6-7), 16c (n=4-19), 17b (n=4), 19c (n=8). Dunnett posttest to compare all columns vs. control column was utilized in Supplementary Fig. 14a (n=4). All graphs represent the mean of at least three biological replicates ± Standard Deviation (SD). Statistical significance is indicated by asterisks: ***=p<0.001; **=p<0.01; *=p<0.05. To identify the T$_H$2 bias of

tissue T_{reg} cells, we used a dataset derived from *in vitro* differentiated T_H1, T_H2, T_H17, and iT_{reg} cells16. Genes specifically up- or down-regulated in T_H2 polarized cells were identified in the comparisons: T_H2 vs. T_H1, T_H2 vs. T_H17, and T_H2 vs. naïve T cells. T_H2-specific genes had to be differential in all three comparisons (>2-fold). We plotted both T_H2-specific gene lists (up and down) on our gene expression dataset (Fat T_{reg} vs. LN T_{reg} and Skin T_{reg} vs. LN T_{reg}). The significance of bias was evaluated by chi square testing.

Data availability

Fastq files from TWGBS, RNA-Seq, and single-cell RNA-Seq that support the findings of this study have been deposited in European Nucleotide Archive (ENA) with the accession code PRJEB14591 (http://www.ebi.ac.uk/ena/data/view/PRJEB14591).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30:531–564. [PubMed: 22224781]

2. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010; 10:490–500. [PubMed: 20559327]

3. Panduro M, Benoist C, Mathis D. Tissue Tregs. Annu Rev Immunol. 2016; 34:609–633. [PubMed: 27168246]

4. Feuerer M, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009; 15:930–939. [PubMed: 19633656]

5. Cipolletta D, et al. PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature. 2012; 486:549–553. [PubMed: 22722857]

6. Vasanthakumar A, et al. The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat Immunol. 2015; 16:276–285. [PubMed: 25599561]

7. Burzyn D, et al. A special population of regulatory T cells potentiates muscle repair. Cell. 2013; 155:1282–1295. [PubMed: 24315098]

8. Arpaia N, et al. A Distinct Function of Regulatory T Cells in Tissue Protection. Cell. 2015; 162:1078–1089. [PubMed: 26317471]

9. Lavin Y, et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell. 2014; 159:1312–1326. [PubMed: 25480296]

10. Gosselin D, et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell. 2014; 159:1327–1340. [PubMed: 25480297]

11. Cabezas-Wallscheid N, et al. Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA methylome analysis. Cell Stem Cell. 2014; 15:507–522. [PubMed: 25158935]

12. Floess S, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007; 5:e38. [PubMed: 17298177]

13. Ohkura N, et al. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity. 2012; 37:785–799. [PubMed: 23123060]

14. Sefik E, et al. MUCOSAL IMMUNOLOGY. Individual intestinal symbionts induce a distinct population of RORgamma(+) regulatory T cells. Science. 2015; 349:993–997. [PubMed: 26272906]

15. Tindemans I, Serafini N, Di Santo JP, Hendriks RW. GATA-3 function in innate and adaptive immunity. Immunity. 2014; 41:191–206. [PubMed: 25148023]

16. Wei G, et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity. 2009; 30:155–167. [PubMed: 19144320]

17. Molofsky AB, Savage AK, Locksley RM. Interleukin-33 in Tissue Homeostasis, Injury, and Inflammation. Immunity. 2015; 42:1005–1019. [PubMed: 26084021]

18. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010; 10:170–181. [PubMed: 20154735]

19. Maurano MT, et al. Role of DNA Methylation in Modulating Transcription Factor Occupancy. Cell Rep. 2015; 12:1184–1195. [PubMed: 26257180]

20. Li P, et al. BATF-JUN is critical for IRF4-mediated transcription in T cells. Nature. 2012; 490:543–546. [PubMed: 22992523]

21. Zaiss DM, et al. Amphiregulin, a TH2 cytokine enhancing resistance to nematodes. Science. 2006; 314:1746. [PubMed: 17170297]

22. Rosenblum MD, Way SS, Abbas AK. Regulatory T cell memory. Nat Rev Immunol. 2016; 16:90–101. [PubMed: 26688349]

23. Moran AE, et al. T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse. J Exp Med. 2011; 208:1279–1289. [PubMed: 21606508]

24. Stockinger B, Di Meglio P, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol. 2014; 32:403–432. [PubMed: 24655296]

25. Yang H, Zhou J, Lehmann C. GPR55 - a putative "type 3" cannabinoid receptor in inflammation. J Basic Clin Physiol Pharmacol. 2016; 27:297–302. [PubMed: 26669245]

26. Staton PC, et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain. 2008; 139:225–236. [PubMed: 18502582]

27. Kolodin D, et al. Antigen- and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice. Cell Metab. 2015; 21:543–557. [PubMed: 25863247]

28. Edinger M. Driving allotolerance: CAR-expressing Tregs for tolerance induction in organ and stem cell transplantation. J Clin Invest. 2016; 126:1248–1250. [PubMed: 26999608]

29. Schiering C, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014; 513:564–568. [PubMed: 25043027]

30. Barth SD, et al. Treg-Mediated Immune Tolerance and the Risk of Solid Cancers: Findings From EPIC-Heidelberg. J Natl Cancer Inst. 2015; 107

31. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 2007; 8:191–197. [PubMed: 17136045]

32. Rubtsov YP, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008; 28:546–558. [PubMed: 18387831]

33. Lu H, et al. Improved tagmentation-based whole-genome bisulfite sequencing for input DNA from less than 100 mammalian cells. Epigenomics. 2015; 7:47–56. [PubMed: 25687465]

34. Wang Q, et al. Tagmentation-based whole-genome bisulfite sequencing. Nat Protoc. 2013; 8:2022–2032. [PubMed: 24071908]

35. Hovestadt V, et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature. 2014; 510:537–541. [PubMed: 24847876]

36. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25:1754–1760. [PubMed: 19451168]

37. Hansen KD, Langmead B, Irizarry RA. BSmooth: from whole genome bisulfite sequencing reads to differentially methylated regions. Genome Biol. 2012; 13:R83. [PubMed: 23034175]

38. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010; 26:841–842. [PubMed: 20110278]

39. Gu Z, Gu L, Eils R, Schlesner M, Brors B. circlize Implements and enhances circular visualization in R. Bioinformatics. 2014; 30:2811–2812. [PubMed: 24930139]

40. Mathelier A, et al. JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2016; 44:D110–115. [PubMed: 26531826]

41. Foat BC, Morozov AV, Bussemaker HJ. Statistical mechanical modeling of genome-wide transcription factor occupancy data by MatrixREDUCE. Bioinformatics. 2006; 22:e141–149. [PubMed: 16873464]

42. Heinz S, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010; 38:576–589. [PubMed: 20513432]

43. Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013; 29:15–21. [PubMed: 23104886]

44. Anders S, Pyl PT, Huber W. HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015; 31:166–169. [PubMed: 25260700]

45. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15:550. [PubMed: 25516281]

46. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012; 9:357–359. [PubMed: 22388286]

47. Anders S, et al. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nat Protoc. 2013; 8:1765–1786. [PubMed: 23975260]

48. Mallona I, Diez-Villanueva A, Peinado MA. Methylation plotter: a web tool for dynamic visualization of DNA methylation data. Source Code Biol Med. 2014; 9:11. [PubMed: 25260021]

49. Lun AT, McCarthy DJ, Marioni JC. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res. 2016; 5:2122. [PubMed: 27909575]

Figure 1. DNA methylome analysis of tissue-resident T_reg cells.

(**a**) Circos plot illustrating tagmentation-based whole-genome bisulfite sequencing (TWGBS) methylation data for chromosomes 1-19 and sex chromosomes X and Y for fat, skin, liver, and LN T_reg cells and LN T_conv cells. Cumulated methylation values are shown in brackets. Color codes indicate mean methylation and mean methylation difference, respectively. (**b**) Unsupervised hierarchical cluster of 11,744 differentially methylated regions (DMRs) identified via TWGBS of fat, skin, liver, and LN T_reg cells and LN T_conv cells. DMRs were identified as at least 30% differentially methylated in pairwise

comparisons. Three replicates per group are shown, with numbers indicating the respective replicate. Colors indicate low (yellow) or high (blue) DMR methylation. (**c**) Group-wise comparison of DMRs and stratification of DMRs into promoter-resident, intragenic or intergenic based on their genomic location, as shown in more detail in Supplementary Fig. 2d. Numbers are derived from pairwise comparisons of indicated groups. (**d**) Average distance of DMRs from the transcription start site (TSS) of the closest gene. (**e**) Principal Component Analysis (PCA) of the different groups based on DMR methylation. Three replicates per group are shown. Colors indicate cell type, with LN T_{reg} (yellow), LN T_{conv} (green), liver T_{reg} (black), fat T_{reg} (purple) and skin T_{reg} (blue).

Figure 2. Transcriptome analysis of tissue-resident T_{reg} cells and correlation with epigenetic dataset.

(**a**) MA plots calculated from RNA sequencing data of fat vs. LN T_{reg}, skin T_{reg} vs. LN T_{reg} cells, fat vs. skin T_{reg}, and LN T_{reg} vs. T_{conv} cells. Numerators are plotted as mean of normalized counts. Fold changes are presented as log2. Significantly up- or downregulated genes (p<0.05) are highlighted in red, with the respective numbers shown above or below. Selected genes are labeled. (**b**) Unsupervised hierarchical clustering of gene expression data. Three replicates per group are shown, with numbers indicating the respective replicate. (**c**) Unsupervised hierarchical clustering of DMR methylation data. Three replicates per group

are shown. (**d**) Pearson correlation between gene expression and DMR methylation. DMRs were intragenic or within 5kb of the nearest gene. Red line represents the median.

Figure 3. Methylation changes of T$_{reg}$-specific epigenetic signature.
(**a**) Methylation mean difference (LN T$_{reg}$ – LN T$_{conv}$) and corresponding log2 RNA expression for promoter and intragenic DMRs identified between LN T$_{reg}$ and T$_{conv}$ cells. Selected demethylated and upregulated genes are highlighted in red, hypermethylated and downregulated genes in blue. Linear regression line in grey. (**b**) Methylation profile of LN T$_{reg}$ (orange line), LN T$_{conv}$ (green line), Fat T$_{reg}$ (purple line), Skin T$_{reg}$ (blue line) and Liver T$_{reg}$ (grey line) for known T$_{reg}$ function-related genes *Foxp3*, *Ctla4*, *Ikzf2*, *Ikzf4*, *Il2ra*, and *Il2rb*. Each line represents average methylation values derived from three individual

replicates. Little ticks at the bottom of each plot represent location of individual CpGs. Arrows indicate gene direction, black bars gene body regions, red bars annotated promoter regions, blue bars exons. Methylation levels are beta values ranging from 0 (unmethylated) to 1 (methylated). (**c**) Detailed analysis of the *Foxp3* gene with superimposed annotation of introns and exons as well as promoter region (PRO) and conserved non-coding regions 1-3 (CNS). Each circle represents one CpG and the color-code represents degree of methylation from yellow (low) to blue (high). Areas R1-R3 labeled in red represent regions for amplicon-based validation via bisulfite sequencing. (**d-g**) PCR amplicon sequencing of bisulfite-converted genomic DNA. Thymic T_{reg} and T_{reg} precursor cells (**d**), LN T_{reg}, T_{conv} cells and *in vitro* induced T_{reg} cells (iT_{reg}) (**e**), tissue-isolated T_{reg} cells (**f**), and spleen-derived pT_{reg} cells, spleen-derived tT_{reg} cells and splenic Tconv cells (**g**). Yellow represents unmethylated and blue methylated CpG, while numbers depict quantity of analyzed reads.

Figure 4. Identification of epigenetic and transcriptional changes in tissue-resident T_reg cells.
(**a**) Methylation mean difference and corresponding log2 RNA expression plot as described in Fig. 3a for DMRs identified in the comparison fat T_reg vs. LN T_reg (upper panel) and skin T_reg vs. LN T_reg (lower panel). (**b**) Heatmaps of candidates (106 genes) for DMR methylation (left) and gene expression (middle) shown for skin, fat and LN T_reg cells. Right panel, gene expression of candidate genes in T_conv cells isolated from LN, skin and fat. T_reg and T_conv gene expression data were row-normalized together. Color codes indicate high (blue) or low (yellow) methylation (left panel) or high (red) and low (blue) gene expression

(right panel). (**c**) Methylation profiles of indicated genes from (**b**) are plotted. Plots are as described in Fig. 3b. Each line represents average methylation values derived from three individual replicates. Plotted are skin (blue), fat (purple), and LN T$_{reg}$ (yellow) and LN T$_{conv}$ (green).

Figure 5. Validation of the common tissue T_reg signature and identification of tissue-specific patterns.

(**a**) Flow cytometry analysis of TIGIT, KLRG1, ST2, BCL-2, TCF7 and LEF1 in fat, skin and LN T_reg cells (CD19−MHCII−CD3+CD8−CD4+CD25+Foxp3+) and corresponding T_conv cells (CD19−MHCII−CD3+CD8−CD4+CD25− Foxp3−). Contour plots are concatenated files representative of four replicates, quantification at bottom part. Individual mice are shown (n=4). Statistical evaluation based on one-way ANOVA with Bonferoni post-test (***=p<0.001). (**b**) Differences in DMR methylation and gene expression of the comparison

T$_{reg}$ cells from fat vs. skin as described in Fig. 3a. (**c**) Methylation pattern of the gene *Pparg* and corresponding gene expression. Shown are skin (blue), fat (purple), and LN T$_{reg}$ (yellow). Each line represents one individual replicate (n=3). Gene expression is plotted as reads per kilobase per million mapped reads (Rpkm). Significance based on RNA sequencing calculations as described in methods section and indicated by asterisks. (**d**) Methylation of *Itgae* (CD103) and *Gpr55* in skin (blue), fat (purple), and LN T$_{reg}$ (yellow) as in (**c**). Quantification of CD103 data are based on (**e**), where contour plots indicate CD103 expression on T$_{reg}$ cells from LN, fat and skin measured via flow cytometry. Statistical evaluation based on one-way ANOVA with Bonferoni post-test (n=9). Means are shown with standard deviation (SD)

Figure 6. Fat and skin T_reg cells are T_H2-like polarized.

(**a**) Gene Ontology (GO) term analysis of the gene list described in Fig. 4b. (**b**) Methylation profile and protein (GATA-3) or gene expression for *Gata3*, *Irf4*, *Rora* and *Batf* as described in Fig. 3b. Average methylation values derived from three individual replicates are shown for fat T_{reg} (purple), skin T_{reg} (blue), LN T_{reg} (yellow) and LN T_{conv} (green). (**c**) Diagnostic T_H2 up- (red, left panel) or downregulated (blue, right panel) signature genes are plotted for the comparison skin vs. LN T_{reg} (upper panel) and fat vs. LN T_{reg} (lower panel). Numbers indicate the number of genes per site. Individual genes are highlighted. Chi2-test for

proportions. (**d**) Methylation profile and protein or gene expression of *Il1rl1* and *Il10* as described in (**b**). ST2 expression quantification based on Fig. 5a and statistically evaluated with one-way ANOVA (n=4). (**e**) Culture of T_{reg} or T_{conv} cells with 25 ng/mL IL-4 (+) or control (-) followed by qPCR-based evaluation of target gene expression. Statistical evaluation with unpaired two-tailed student's t test (n=4). (**f**) Tissue T_{reg} methylation data were grouped into 4 specific methylation-expression clusters (top panel). Based on these clusters, binding motif enriched factors were calculated and illustrated in a heat map (middle panel). Gene expression values of cluster 2 binding motif enriched factors for fat T_{reg}, skin T_{reg}, liver T_{reg}, LN T_{conv} and LN T_{reg} are shown as heatmap (bottom panel), where colors indicate relative expression (high=red; low=blue). Individual replicates are shown (n=3). Means are shown with SD.

Figure 7. Identification of tisT_regST2 cells.
(**a**) TisT_regST2 cells (CD8^−CD19^−MHCII^−
CD3^+CD4^+CD25^+Foxp3^+ST2^+KLRG1^+GATA-3^+) population (R1) and identification of this
population in different tissues. KLRG1^−ST2^− T_reg cells served as controls (R2). Contour
plots and histograms are based on concatenated files of four or more biological replicates.
(**b**) Quantification of tisT_regST2 frequency in different tissues. (**c**) Frequency distribution of
tisT_regST2 in pT_reg and tT_reg population in the colon. pT_reg cells were defined as CD8^−
CD19^−MHCII^−CD4^+CD25^+Foxp3^+HELIOS^−RORγt^+, and tT_reg were defined as CD8^−

CD19$^-$MHCII$^-$CD4$^+$CD25$^+$Foxp3$^+$HELIOS$^+$RORγt$^-$. tisT$_{reg}$ST2 were identified as KLRG1$^+$ST2$^+$ of the respective T$_{reg}$ type. Statistical evaluation with two-tailed unpaired student's t test (n=10). (**d**) Spleen cells were stimulated as described. TisT$_{reg}$ST2 cells were identified as CD45$^+$TCRβ$^+$CD4$^+$CD8$^-$Foxp3$^+$KLRG1$^+$ST2$^+$ cells (R2, red) and stained for intracellular expression of AREG and IL-10. KLRG1$^-$ST2$^-$ T$_{reg}$ cells (R1, blue) were used as control. Right panel, quantification. Statistical evaluation with one-way ANOVA and Bonferoni post-test (n=4). Additional controls shown in Supplementary Fig. 19. (**e**) TisT$_{reg}$ST2 from spleen (tisT$_{reg}$ST2 Spl) and ST2$^-$KLRG1$^-$ T$_{reg}$ cells (T$_{reg}$ Spl) from spleen were isolated using FACS and expression of different genes was analyzed via qPCR. Color code depicts gene expression value (red=high, blue=low). (**f**) Methylation of CG dinucleotides at the *Gata3*, *Klrg1* and *Lef1* DMR locus is shown for indicated groups, with blue indicating high and yellow indicating low methylation levels. (**g**) Expression of *Grp55* and *Pparg*, based on the gene expression dataset derived from (**e**). (**h**) scRNASeq analysis of 101 tisT$_{reg}$ST2 cells derived from spleen. Gene expression of tisT$_{reg}$ST2-associated markers *Helios, Gata3, Klrg1, Tigit*, and skin associated marker *Itgae, Ahr and Gpr55*. t-SNE analysis of single tisT$_{reg}$ST2 cells with a skin T$_{reg}$ signature. Expression of *Ahr* is indicated by dot size. Means are shown with SD.

Figure 8. Characterization of the tisT_regST2 population.

(**a**) Frequency of tisT_regST2 in mice. Data are derived from fat, skin, lymph nodes and spleen from mice of 5, 10, 15, 20, and 25 weeks of age. TisT_regST2 were gated as described in Fig. 7. Additional plots are shown in Supplementary Fig. 21. Contour plots are concatenated files representative of five replicates. (**b**) CD45.2$^+$KLRG1$^-$ST2$^-$ T_reg cells were isolated from CD45.2$^+$ Foxp3^{Cre,YFP} donor animals and injected into DT-treated CD45.1$^+$ Foxp3^{GFP,DTR} recipients. After ten days, presence of tisT_regST2 was evaluated by flow cytometry. Contour plots are representative examples of four replicates. (**c**) Gene-

expression analysis of *in vitro* cultivated and activated tisT$_{reg}$ST2 (fat) and KLRG1$^-$ST2$^-$ (spleen) T$_{reg}$ cells. Cultivated for six days with anti-CD3 and anti-CD28 microbeads and IL-2. Gene expression of tisT$_{reg}$ST2 genes was measured by qPCR. Colors indicate gene expression levels with red=high and blue=low relative expression. (**d**) Flow cytometry anaylsis of T$_{reg}$ cells in tissues of Batf-deficient mice (Batf$^{-/-}$) versus Batf-sufficient wildtype mice (Batf$^{+/+}$). Dot plots are concatenated files representative of six to ten replicates. Individual mice are shown. Statistical evaluation based on two-tailed unpaired student's t test (n=6-10). (**e**) Flow cytometry analysis of T$_{reg}$ cells in tissues of wildtype mice treated with of IL-33 or PBS. Dot plots are concatenated files representative of four replicates. Additional plots are shown in Supplementary Fig. 21. Individual mice are shown. Statistical evaluation based on two-tailed unpaired student's t test (n=4). Means are shown with SD.

Antibodies		
Pacific Blue anti-mouse CD3epsilon antibody	Biolegend	AB_2028475
Brilliant Violet 711 anti-mouse CD3 antibody	Biolegend	AB_2563945
APC anti-mouse CD4 antibody	Biolegend	AB_312719
APC/Cy7 anti-mouse CD4 antibody	Biolegend	AB_312699
Biotin anti-mouse CD4 antibody	Biolegend	AB_312711
Brilliant Violet 421 anti-mouse CD4 antibody	Biolegend	AB_11219790
FITC anti-mouse CD4 antibody	Biolegend	AB_312713
Brilliant Violet 711 anti-mouse CD4 antibody	Biolegend	AB_2562099
Brilliant Violet 605 anti-mouse CD4 antibody	Biolegend	AB_2563054
PE anti-mouse CD4 antibody	Biolegend	AB_312715
PE/Cy7 anti-mouse CD4 antibody	Biolegend	AB_312729
PerCP/Cy5.5 anti-mouse CD4 antibody	Biolegend	AB_893326
Brilliant UV 395 anti-mouse CD4 antibody	BD Biosciences	Cat# 563790
Brilliant UV 737 anti-mouse CD4 antibody	BD Biosciences	Cat# 564933
Biotin anti-mouse CD8a antibody	Biolegend	AB_312743
PE/Cy7 anti-mouse CD8a antibody	Biolegend	AB_312761
PerCP/Cy5.5 anti-mouse CD8a antibody	Biolegend	AB_2075238
Biotin anti-mouse/human CD11b antibody	Biolegend	AB_312787
Biotin anti-mouse CD11c antibody	Biolegend	AB_313773
APC/Cy7 anti-mouse CD19 antibody	Biolegend	AB_830707
Biotin anti-mouse CD19 antibody	Biolegend	AB_313639
APC anti-mouse CD25 antibody	Biolegend	AB_312861
Biotin anti-mouse CD25 antibody	Biolegend	AB_312853
PE anti-mouse CD25 antibody	Biolegend	AB_312857
PE/Cy7 anti-mouse CD25 antibody	Biolegend	AB_312865
Brilliant Violet 711 anti-mouse CD25 antibody	Biolegend	AB_2564130
Pacific Blue anti-mouse/human CD44 antibody	Biolegend	AB_493683
Brilliant Violet 421 anti-mouse/human CD44 antibody	Biolegend	AB_10895752
Brilliant Violet 605 anti-mouse/human CD44 antibody	Biolegend	AB_2562451
Brilliant Violet 421 anti-mouse CD45 antibody	Biolegend	AB_10899570
APC/Cy7 anti-mouse CD45 antibody	Biolegend	AB_312981
Pacific Blue anti-mouse CD45 antibody	Biolegend	AB_493535
Biotin anti-mouse CD49b (pan-NK cells) antibody	Biolegend	AB_313411
APC anti-mouse CD62L antibody	Biolegend	AB_313099
APC/Cy7 anti-mouse CD62L antibody	Biolegend	AB_830799
PerCP/Cy5.5 anti-mouse CD62L antibody	Biolegend	AB_2285839
Alexa Fluor 647 anti-mouse CD103 antibody	Biolegend	AB_535952
PE anti-mouse CD103 antibody	Biolegend	AB_1133989

Brilliant Violet 605 anti-mouse CD127 (IL-7Ralpha) antibody	Biolegend	AB_2562114
Brilliant Violet 421 anti-mouse CD127 (IL-7Ralpha) antibody	Biolegend	AB_11218800
PE anti-mouse CD200 R (OX2R) antibody	Biolegend	AB_2074080
PE/Cy7 anti-mouse I-A/I-E antibody	Biolegend	AB_2290801
Pacific Blue anti-mouse I-A/I-E antibody	Biolegend	AB_493527
APC/Cy7 anti-mouse I-A/I-E antibody	Biolegend	AB_1659252
PE anti-mouse/human KLRG1 (MAFA) antibody	Biolegend	AB_10574005
Brilliant Violet 421 anti-mouse/human KLRG1 antibody	Biolegend	AB_2565613
Brilliant Violet 605 anti-mouse/human KLRG1 antibody	Biolegend	AB_2563357
Anti-Mouse ST2 (IL-33R) biotinylated antibody	Affymetrix eBioscience	AB_2572809
Brilliant Violet 421 anti-mouse IL-33R (ST2) antibody	Biolegend	AB_2565634
PE anti-mouse IL-33R (ST2) antibody	Biolegend	AB_2561914
PE anti-mouse TIGIT (Vstm3) antibody	Biolegend	AB_10895760
PE/Cy7 anti-mouse TIGIT (Vstm3) antibody	Biolegend	AB_2565649
Mouse Amphiregulin biotinylated affinity Purified PAb antibody	R and D Systems	AB_2060662
Alexa Fluor 647 anti-Bcl-2 antibody	Biolegend	AB_2274702
Alexa Fluor 488 anti-Bcl-2 antibody	Biolegend	AB_2028390
Anti-Mouse/Rat Foxp3 Alexa Fluor 647 antibody	Biolegend	AB_763538
Anti-Mouse/Rat Foxp3 Biotin antibody	Biolegend	AB_763540
Anti-Mouse/Rat Foxp3 PE antibody	Biolegend	AB_465936
Alexa Fluor 647 anti-GATA3 antibody	Biolegend	AB_2563217
PE anti-GATA3 antibody	Biolegend	AB_2562723
PE anti-mouse IL-10 antibody	Biolegend	AB_315362
Anti-Human/Mouse T-bet PE antibody	Biolegend	AB_925762
LEF1 (C12A5) Rabbit mAb antibody	Biolegend	AB_823558
TCF1 (C63D9) Rabbit mAb antibody	Biolegend	AB_2199302
PE anti-mouse human HELIOS antibody	Biolegend	AB_10660749
Brilliant V 421 anti-mouse Rorγt antibody	BD Biosciences	Cat# 562894
Goat Anti-Rabbit IgG (H+L) antibody, Alexa Fluor 647 Conjugated	Thermo Fisher	AB_10562581
Fixable Viability Dye eFluor 506	Affymetrix eBioscience	Cat# 65-0866-18
Fixable Viability Dye eFluor 780	Affymetrix eBioscience	Cat# 65-0865-18
APC/Cy7 Streptavidin	Biolegend	Cat# 405208
eFluro450 Streptavidin	Affymetrix eBioscience	Cat# 48-4317-82
FITC Streptavidin	Biolegend	Cat# 405201
PE Streptavidin	Biolegend	Cat# 405204
PE/Cy7 Streptavidin	Biolegend	Cat# 405206
PerCP/Cy5.5 Streptavidin	Biolegend	Cat# 405214
Brilliant UV 395 Streptavidin	BD Biosciences	Cat# 564176
Brilliant UV 737 Streptavidin	BD Biosciences	Cat# 564293
APC Streptavidin	Biolegend	Cat# 405207

Brilliant Violet 421 Streptavidin	Biolegend	Cat# 504421
Brilliant Violet 421 Streptavidin	Biolegend	Cat# 504421
Primers & Probes		
Taqman Probe for *Hprt*	Thermo Fisher	Mm01318746_g1
Taqman Probe for *Il2ra*	Thermo Fisher	Mm01340213_m1
Taqman Probe for *Foxp3*	Thermo Fisher	Mm00475162_m1
Taqman Probe for *Il7r*	Thermo Fisher	Mm00434295_m1
Taqman Probe for *Pparg*	Thermo Fisher	Mm01184322_m1
Taqman Probe for *Tbx21*	Thermo Fisher	Mm00450960_m1
Taqman Probe for *Irf4*	Thermo Fisher	Mm00516431_m1
Taqman Probe for *Gata3*	Thermo Fisher	Mm00484683_m1
Taqman Probe for *Il10*	Thermo Fisher	Mm01288386_m1
Taqman Probe for *Il1rl1*	Thermo Fisher	Mm00516117_m1
Taqman Probe for *Rora*	Thermo Fisher	Mm01173766_m1
Taqman Probe for *Areg*	Thermo Fisher	Mm00452865_m1
Taqman Probe for *Osbpl3*	Thermo Fisher	Mm00452865_m1
Taqman Probe for *Tcf7*	Thermo Fisher	Mm00493445_m1
Taqman Probe for *Lef1*	Thermo Fisher	Mm00550265_m1
Taqman Probe for *Lmna*	Thermo Fisher	Mm00497783_m1
Taqman Probe for *Ms4a4b*	Thermo Fisher	Mm00649916_m1
Taqman Probe for *Klrg1*	Thermo Fisher	Mm00516879_m1
Taqman Probe for *Tigit*	Thermo Fisher	Mm03807522_m1
Taqman Probe for *Foxp1*	Thermo Fisher	Mm00474848_m1
Taqman Probe for *Batf*	Thermo Fisher	Mm00479410_m1
Taqman Probe for *Grp55*	Thermo Fisher	Mm02621622_s1
Bisulfite-DNA primer for *Foxp3* Upstream R1	Forward Primer	AGGATGTTAGG GTATTAAAGGT TGG
Bisulfite-DNA primer for *Foxp3* Upstream R1	Reverse Primer	CCAATTTTCCT AAAACCAACA ATAT
Bisulfite-DNA primer for *Foxp3* R2 (R2.1)	Forward Primer	AGTGTTTAGTT TTTGTTTTTTTT TTAGGTTTTG
Bisulfite-DNA primer for *Foxp3* R2 (R2.1)	Forward Primer	TCTTACRTAAC ACAAACAAAA AATCAATTAAA TAC
Bisulfite-DNA primer for *Foxp3* R2 (R2.2)	Reverse Primer	GTTGTGGTATT GTGTTTGGTAT ATG
Bisulfite-DNA primer for *Foxp3* R2 (R2.2)	Forward Primer	ACACTTAATTC AAATAATCAAA TTCATAAT
Bisulfite-DNA primer for *Foxp3* R3 (TSDR)	Reverse Primer	TGGGTTTTTTT GGTATTTAAGA AAG

Bisulfite-DNA primer for *Foxp3* R3 (TSDR)	Forward Primer	AAAAAACAAA TAATCTACCCC ACAA
Bisulfite-DNA primer for *Foxp3* R4 (Exon 8)	Forward Primer	TGAAAGGTTAT AATGAAATGAT AAGTTTAA
Bisulfite-DNA primer for *Foxp3* R4 (Exon 8)	Forward Primer	ATTACCATAAC TTCCCCAAAA ATAC
Bisulfite-DNA primer for *Foxp3* R5 (Exon 11)	Forward Primer	TGATTGTTAAT TTTGTTTTTGA TTG
Bisulfite-DNA primer for *Foxp3* R5 (Exon 11)	Reverse Primer	CAACCTCAATC TCATAATTTTA ACC
Bisulfite-DNA primer for *Gata3* DMR	Forward Primer	AGAAGGGAAG AAAAATAAAG GAGAGAAAAT TATTAG
Bisulfite-DNA primer for *Gata3* DMR	Reverse Primer	CCTCCCTCATC ATTCTAAATATT ACCTC
Bisulfite-DNA primer for *Klrg1* DMR	Forward Primer	GAGTTGGGGT AGTAGAGAGTT TTATTTTG
Bisulfite-DNA primer for *Klrg1* DMR	Reverse Primer	ACTATACCTCA TAAATATATACA ATCACTATCTC TCC
Bisulfite-DNA primer for *Lef1* DMR	Forward Primer	TTGTTGTTAAT TGGGGAAATAT TTGAAGTTGTT G
Bisulfite-DNA primer for *Lef1* DMR	Reverse Primer	AACRTAAAACT AAAAACAAAC AACTAATTATA ACC
Bisulfite-DNA primer for *Ctla4* Exon 2 (derived from 13)	Forward Primer	TGGTGTTGGTT AGTAGTTATGG TGT
Bisulfite-DNA primer for *Ctla4* Exon 2 (derived from 13)	Reverse Primer	AAATTCCACCT TACAAAAATAC AATC
Bisulfite-DNA primer for *Ikzf2* Intron 3a (derived from 13)	Forward Primer	AGGATGGTTTT TATTGAAGGTG AT
Bisulfite-DNA primer for *Ikzf2* Intron 3a (derived from 13)	Reverse Primer	ATACACACCAA ACAAACACTAC ACC
Bisulfite-DNA primer for *Il2ra* Intron 1a (derived from 13)	Forward Primer	TTTTAGAGTTA GAAGATAGAA GGTATGGAA
Bisulfite-DNA primer for *Il2ra* Intron 1a (derived from 13)	Reverse Primer	TCCCAATACTT AACAAAACCA CATAT
Critical Chemicals		
Collagenase II	Sigma Aldrich	Cat# C6885
Collagenase IV	Sigma Aldrich	Cat# C5138

Bovine Serum Albumin BSA	Sigma Aldrich	Cat# A4503
DNAse	Roche	Cat# 11284932001
Ez-Tn5 transposase	Epicentre	Cat# EZI011RK
Bst DNA polymerase	New England Biolabs	Cat# M0275S
5mC-dNTP mix	Zymo Research	Cat# D1030
Power SYBR Green Master Mix	Thermo Fisher	Cat# 4367659
Taqman Gene Expression Master Mix	Thermo Fisher	Cat# 4359016
NEBNext Multiplex Oligos for Illumina	New England Biolabs	Cat# E7335, E7500
NEBNext High Fidelity 2x PCR Master Mix	New England Biolabs	Cat# M0541
SuperScript II Reverse Transcriptase	Thermo Fisher Scientific	Cat# 18064071
Oligo d(T) 12-18 Primer	Thermo Fisher	Cat# 18418012
Anti-biotin Microbeads	Miltenyi Biotec	Cat# 130-090-385
Dynebeads Mouse T-Activator CD3/CD28	Thermo Fisher	Cat# 11456D
Anti-Mouse IL-12/IL-23 p40 Functional Grade Purified 500 ug Antibody	Affymetrix eBioscience	AB_469233
Purified anti-mouse IFN-gamma antibody	Biolegend	AB_315396
Recombinant murine IL-2	Peprotech	Cat# 212-12
Recombinant murine IL-4	Peprotech	Cat# 214-14
Recombinant murine IL-33	Biolegend	Cat# 580506
Recombinant human TGF-beta	Peprotech	Cat# 100-21
PMA/Ionomycin stim cocktail plus transport inhibitors	Affymetrix eBioscience	Cat# 00-4975-03
Marimastat	Sigma Aldrich	Cat# M2699
Critical Commercial Kits		
Quick gDNA Microprep Kit	Zymo Research	Cat# D3020
RNEasy Mini Kit	Quiagen	Cat# 74104
Ampure Beads	Beckman Coulter	Cat# A63881
EZ DNA methylation kit	Zymo Research	Cat# D5002
Kapa 2G Robust HotStart ReadyMix	Kapa Biosystems	Cat# KK5701
Smarter Ultra Low Input RNA	Clontech Labs	Cat# 634888
NEXT ChIP-Seq Library Prep Master Mix	New England Biolabs	Cat# E6240
QIAamp DNA micro kit	Quiagen	Cat# 56304
DNEasy Blood and Tissue kit	Quiagen	Cat# 69504
EpiTect Bisulfite conversion kit	Zymo Research	Cat# 59104
PureLink Quick Gel Extraction Kit	Thermo Fisher	Cat# K210012
Foxp3 / Transcription Factor Staining Buffer Set	Affymetrix eBioscience	Cat# 00-5523-00